Histo-blood group antigens (HBGAs) expressed on enterocytes are proposed receptors for rotaviruses and can be measured in saliva. Among 181 Pakistani infants in a G1P[8] rotavirus vaccine trial who were seronegative at baseline, anti-rotavirus immunoglobulin A seroconversion rates after 3 vaccine doses differed significantly by salivary HBGA phenotype, with the lowest rate (19%) among infants who were nonsecretors (ie, who did not express the carbohydrate synthesized by FUT2), an intermediate rate (30%) among secretors with non-blood group O, and the highest rate (51%) among secretors with O blood group. Differences in HBGA expression may be responsible for some of the discrepancy in the level of protection detected for the current rotavirus vaccines in low-income versus high-income settings.
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Certain histo-blood group antigens (HBGAs) expressed on enterocytes have been proposed as receptors or ligands for the VP8* of rotaviruses; VP8* is the globular head fragment of the spike protein, VP4 [1] [2] [3] . The protease-sensitive (P) protein VP4 and the glycoprotein (G) VP7 are the 2 major outer surface proteins of rotaviruses, and the sequences of genes encoding these proteins are used to classify rotaviruses by their P and G genotypes, respectively. Epidemiologic associations have been reported between particular HBGA types and disease (or lack of disease) from particular human rotavirus P genotypes [4] [5] [6] [7] . In a rotavirus vaccine trial among rotavirus-naive infants, we examined differences in infection rates (ie, vaccine take, defined by anti-rotavirus immunoglobulin A [IgA] seroconversion) following standardized challenge with a specific vaccine strain, based on these proposed host susceptibility factors. The vaccine trial (clinical trials registration NCT01199874) was conducted in Karachi, Pakistan, to evaluate the impact of breastfeeding or temporarily withholding breastfeeding at the time of receiving Rotarix vaccine (GSK Biologicals, Rixensart, Belgium) at ages 6, 10, and 14 weeks [8] . Rotarix contains an attenuated human G1P [8] rotavirus strain. Saliva and serum samples were collected at ages 6, 14, and 18 weeks from infants who had been randomly assigned to the arm in which breastfeeding was withheld.
METHODS
Before we conducted this study, informed consent had been obtained for all participants in the clinical trial [8] and the protocol had been approved by the institutional review board at each participating institution. We evaluated infants in the withholding-breastfeeding arm so that the saliva sample collected just before vaccine receipt would not be contaminated with breast milk. Seventy-six percent of infants were being exclusively breastfed at time of enrollment. Infants assigned to the withholding-breastfeeding arm were monitored to be without breastfeeding (or any other feeding) for 1 hour before and after receipt of each rotavirus vaccine dose. The saliva sample was collected by the study nurse just before the administration of the vaccine doses at 6 and 14 weeks and after a period of withheld-breastfeeding during transport to and registration at the clinic at age 18 weeks.
For each of the 181 infants in the arm in which the trial was completed per protocol, the HBGA phenotype was determined by testing saliva samples for carbohydrates synthesized by enzymes encoded by FUT2 (fucosyltransferase 2; the so-called secretor gene), FUT3 (the so-called Lewis gene), and the ABO gene, namely, H antigen, Lewis a and b antigens, and A and B blood group antigens, respectively. HBGA testing of saliva samples collected at age 14 weeks was performed using enzyme immunoassays (EIAs) and commercially available lectin and anti-HBGA antibodies (Supplementary Materials). If results were unclear, testing was repeated using the 6-and 18-week saliva samples. For each infant, test results were used to classify infants as positive or negative for the secretor, Lewis, and A or B blood group antigens. The laboratory staff testing saliva were blinded to serum testing results, and vice versa.
The concentrations of anti-rotavirus IgA antibody in serum from the infants collected at ages 6, 14, and 18 weeks had been determined using EIAs, as previously described [8] . Preexisting neutralizing antibodies, presumed to be maternally derived (MDNAs), were measured in serum collected at 6 weeks by a neutralization assay against rotavirus strain 89-12, the precursor to the Rotarix vaccine strain [8, 9] . As per the trial, seroconversion was defined as anti-rotavirus IgA antibody levels of ≥20 U/mL at either age 14 weeks (4 weeks following dose 2 of vaccine) or 18 weeks (4 weeks following dose 3) among infants seronegative (IgA level, <20 U/mL) at age 6 weeks before dose 1. Infants with an IgA level of ≥20 U/ ml in the 6-week serum sample were excluded from analysis, as in the trial (n = 3).
Relative risks (RR) of seroconversion, stratified by secretor, Lewis, and A or B antigen in saliva specimens, were estimated using binomial log-linear regression. Covariates planned a priori to assess for possible confounding included level of antirotavirus MDNA in the infant's 6-week serum sample (by quartile) and exposure to a season of higher wild-type rotavirus circulation (November-February) between ages 6 and 18 weeks. Baseline demographic and household variables were compared in univariate analyses between infants who seroconverted and those who did not; factors with a P value of <.05 by the χ 2 test and nutritional status were also assessed as possible confounders in the models (Supplementary Materials). Confounding was assessed by backward elimination; factors whose elimination changed the risk ratio of the variable of interest (secretor and blood group) by ≥10% were retained in the model. The level of rotavirus neutralizing activity in breast milk samples (assessed using a neutralization assay targeting the vaccine strain [9] ) collected when the infants were aged 10 weeks was highly positively correlated with the MDNA level at age 6 weeks [8] were similar (or point estimates were modestly higher) when Lewis antigen-negative infants were excluded (data not shown).
Results were similar to all of those described above when the outcome was limited to seroconversion at age 14 weeks, after receipt of 2 doses of vaccine (data not shown).
The serum anti-rotavirus IgA concentration was not correlated with the OD from the salivary UEA-1 lectin EIA result among secretors (ρ = 0.10, P = .28) nor among secretors who seroconverted (ρ = 0.15, P = .32). Examination of the 56 infants who seroconverted showed that the serum anti-rotavirus IgA concentrations were not statistically different between any 2 groups (O, Se-vs O, Se+ vs A and/or B, Se+).
DISCUSSION
We have demonstrated that seroconversion following receipt of oral attenuated human G1P [8] rotavirus vaccine is associated with secretor and salivary ABO blood group antigen status of young infants. These in vivo data, involving a standardized exposure to a specific rotavirus strain, concomitant measurement of HBGA expression, and assessment for potential confounders, complement the recent elucidations in the proposed mechanisms of VP8* binding believed to be necessary for intestinal epithelial cell infection by human rotaviruses.
HBGAs are synthesized by glycosyltransferases encoded by ABO, Lewis, and secretor gene families. Recent investigations have suggested that the sialic acid-independent human rotaviruses recognize certain HBGAs in a P genotype-dependent manner. VP8* sequencing identified segregation of animal and human rotaviruses into 5 P genogroups, and researchers have hypothesized that strains within a genogroup may interact with a specific HBGA epitope [2] . In our study, nonsecretors had the lowest rate of seroconversion, although this was not an absolute restriction against presumed vaccine-strain infection and resultant seroconversion. This finding is consistent with in vitro data that demonstrated recombinant and cell-culture-adapted P [8] strains interacted with Lewis b and H type 1 antigens (carbohydrates expressed only in individuals with functional FUT2 alleles) [1] and that Rotarix VP8*-GST fusion protein bound to saliva samples from secretors but not those from nonsecretors [10] . In vitro findings have not been consistent, however. Rotarix VP8* did not bind to synthetic H type 1 and Lewis b oligosaccharides [9] , and nuclear magnetic resonance spectroscopy revealed that the human Wa (P[8]) strain did not recognize H type 1 or Lewis b antigens [10] . Epidemiological evaluations with some population diversity have found that children with rotavirus disease from P [8] strains are significantly more likely to be secretors (meta-analysis pooled odds ratio, 26.6), compared with the general population [12] . Epidemiological data from one location have also suggested that children with rotavirus disease from P [6] strains are more likely to be Lewis negative [4] .
Our data demonstrating that the highest likelihood of seroconversion is among type O secretors is consistent with in vitro saliva binding assay results that led investigators to propose that the type B epitope may interfere with binding of P [8] strains by masking the H epitope; lower binding, however, was not observed with the A epitope [1] .
Limitations of the evaluation should be noted. We did not find Lewis antigen status to be independently associated with vaccine take at a statistically significant level, but our sample size of Lewis antigen-negative infants was small, consistent with the relatively modest prevalence of this phenotype in many populations (approximately 10%-12%). As with all rotavirus vaccine serological evaluations performed in countries where some wild-type rotavirus circulation occurs year-round, which precludes performing the evaluation only during the nonrotavirus season, some infants in our trial may have seroconverted because of wild-type infection. To help address the potential impact of wild-type infection on our results, we assessed for confounding or effect modification by peak rotavirus season, and found no evidence of this. The associations detected between secretor/HBGA status and seroconversion after vaccine receipt were not different for children who had passed through the rotavirus season and those who had not. In Pakistan, non-P [8] strains are not uncommon; for example, from 2008-2009 data from surveillance sites that included Karachi, P [6] strains accounted for 31.5% of those that were genotyped [13] . To further examine how our results might have been affected if some seroconversion was from wild-type exposure, we excluded infants proposed to be most susceptible to disease from P [6] genotypes (ie, Lewis antigen-negative infants); the results were similar to the original findings. Finally, our results are based on salivary phenotype at the time of vaccine exposure, as an indirect measure of the proposed gold standard-gut carbohydrate phenotype at time of exposure-which is not directly measurable in free-living subjects. We were unable to measure HBGA genotypes, but genotype is not clearly superior for HBGA typing. Some genetic secretors have low H antigen expression, such that their phenotype and epidemiologic risk can be similar to that of nonsecretors [14] . While the currently available vaccines have been a longawaited reality to combat the high morbidity and mortality from rotavirus disease in low-income settings, improved performance of rotavirus vaccines in these settings to reach that achieved in high-income locations would be of great public health value. To that end, a better understanding of how and the extent to which expression of HBGAs, in different populations, influence protection against rotavirus disease (and our measurement of this protection) is important. These data also illustrate how vaccines may move further into the realm of personalized medicine, being tailored to an individual's genetic capacity to elicit a protective response against genotypes to which they are susceptible [15] .
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